Our results contribute to the theoretical foundation for novel therapeutic strategies that may involve targeting the CXCL12/CXCR4 pathway modulated by CAFs, with the ultimate goal of improving cancer outcomes across species. This evidence concerns the gene CXCR4 and cancer.